Venous thromboembolism hazard ratios by HDL2, HDL3, and ApoA-I quartiles, ARIC
| . | HDL2 quartile . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Men | ||||
| HDL2, mg/dL | 0 to <6.74 | 6.74 to <9.63 | 9.63 to <13.5 | 13.5 to 95.3 |
| Number of events | 28 | 27 | 37 | 29 |
| Hazard ratio* | 1.19 | 0.97 | 1.29 | 1.00 |
| 95% CI | (0.69-2.03) | (0.57-1.67) | (0.78-2.13) | Ref. |
| Women | ||||
| HDL2, mg/dL | 0 to <10.6 | 10.6 to <15.4 | 15.4 to <21.2 | 21.2 to 92.5 |
| Number of events | 43 | 43 | 32 | 29 |
| Hazard ratio* | 1.17 | 1.14 | 1.07 | 1.00 |
| 95% CI | (0.70-1.98) | (0.69-1.90) | (0.63-1.82) | Ref. |
| . | HDL2 quartile . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Men | ||||
| HDL2, mg/dL | 0 to <6.74 | 6.74 to <9.63 | 9.63 to <13.5 | 13.5 to 95.3 |
| Number of events | 28 | 27 | 37 | 29 |
| Hazard ratio* | 1.19 | 0.97 | 1.29 | 1.00 |
| 95% CI | (0.69-2.03) | (0.57-1.67) | (0.78-2.13) | Ref. |
| Women | ||||
| HDL2, mg/dL | 0 to <10.6 | 10.6 to <15.4 | 15.4 to <21.2 | 21.2 to 92.5 |
| Number of events | 43 | 43 | 32 | 29 |
| Hazard ratio* | 1.17 | 1.14 | 1.07 | 1.00 |
| 95% CI | (0.70-1.98) | (0.69-1.90) | (0.63-1.82) | Ref. |
| . | HDL3 quartile . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Men | ||||
| HDL3, mg/dL | 1.93 to <27.0 | 27.0 to <32.7 | 32.7 to <39.5 | 39.5 to 86.7 |
| Number of events | 30 | 28 | 24 | 39 |
| Hazard ratio* | 0.72 | 0.76 | 0.65 | 1.00 |
| 95% CI | (0.44-1.19) | (0.46-1.25) | (0.39-1.09) | Ref. |
| Women | ||||
| HDL3, mg/dL | 2.00 to <33.0 | 33.0 to <40.5 | 40.5 to <47.2 | 47.2 to 99.0 |
| Number of events | 33 | 49 | 28 | 37 |
| Hazard ratio* | 0.78 | 1.24 | 0.78 | 1.00 |
| 95% CI | (0.46-1.32) | (0.78-1.97) | (0.46-1.31) | Ref. |
| . | HDL3 quartile . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Men | ||||
| HDL3, mg/dL | 1.93 to <27.0 | 27.0 to <32.7 | 32.7 to <39.5 | 39.5 to 86.7 |
| Number of events | 30 | 28 | 24 | 39 |
| Hazard ratio* | 0.72 | 0.76 | 0.65 | 1.00 |
| 95% CI | (0.44-1.19) | (0.46-1.25) | (0.39-1.09) | Ref. |
| Women | ||||
| HDL3, mg/dL | 2.00 to <33.0 | 33.0 to <40.5 | 40.5 to <47.2 | 47.2 to 99.0 |
| Number of events | 33 | 49 | 28 | 37 |
| Hazard ratio* | 0.78 | 1.24 | 0.78 | 1.00 |
| 95% CI | (0.46-1.32) | (0.78-1.97) | (0.46-1.31) | Ref. |
| . | ApoA-I quartile . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Men | ||||
| ApoA-I, mg/L | 380 to <1030 | 1030 to <1190 | 1190 to <1360 | 1360 to 3040 |
| Number of events | 30 | 26 | 27 | 38 |
| Hazard ratio* | 0.88 | 0.67 | 0.77 | 1.00 |
| 95% CI | (0.53-1.44) | (0.40-1.12) | (0.47-1.25) | Ref. |
| Women | ||||
| ApoA-I, mg/L | 200 to <1210 | 1210 to <1400 | 1400 to <1610 | 1610 to 3040 |
| Number of events | 40 | 38 | 34 | 35 |
| Hazard ratio* | 1.01 | 0.98 | 0.89 | 1.00 |
| 95% CI | (0.61-1.68) | (0.60-1.61) | (0.54-1.47) | Ref. |
| . | ApoA-I quartile . | |||
|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | |
| Men | ||||
| ApoA-I, mg/L | 380 to <1030 | 1030 to <1190 | 1190 to <1360 | 1360 to 3040 |
| Number of events | 30 | 26 | 27 | 38 |
| Hazard ratio* | 0.88 | 0.67 | 0.77 | 1.00 |
| 95% CI | (0.53-1.44) | (0.40-1.12) | (0.47-1.25) | Ref. |
| Women | ||||
| ApoA-I, mg/L | 200 to <1210 | 1210 to <1400 | 1400 to <1610 | 1610 to 3040 |
| Number of events | 40 | 38 | 34 | 35 |
| Hazard ratio* | 1.01 | 0.98 | 0.89 | 1.00 |
| 95% CI | (0.61-1.68) | (0.60-1.61) | (0.54-1.47) | Ref. |
Multivariable model adjusted for the following covariates at baseline: age, race, BMI, diabetes, factor VIIIc, pack-years of smoking, and HRT use in women.